# Tofacitinib

## Xeljanz 5mg

##### 臨採

| TAH Drug Code      | [OXELJ](https://www.tahsda.org.tw/drugs/hissearch.php?drug_code=OXELJ                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                 |
|:-------------------|:------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| Indications        | Rheumatoid arthritis (Moderate to Severe), Psoriatic arthritis, Ankylosing spondylitis, Ulcerative colitis (Moderate to Severe)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                       |
| Dosing             | Rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis: 5 mg orally twice daily. Ulcerative colitis induction dose 10 mg orally twice daily (8-16 weeks), maintenance dose 5 mg orally twice daily.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        |
| Hepatic Impairment | Dose adjustment required                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| Renal Impairment   | Dose adjustment required                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                              |
| Contraindications  | Hypersensitivity to tofacitinib or any component of the formulation                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                   |
| Adverse Effects    | Common: Increased HDL level (10-12%), Low density lipoprotein cholesterol above reference range (15-19%), Headache (3.4-9%), Urinary tract infectious disease (2%), Nasopharyngitis (2.8-14%), Upper respiratory infection (3.8-6%) Serious: Cardiovascular morbidity, Major adverse cardiac events (MACE), Death, Cardiovascular, Myocardial infarction, Skin cancer, Non-melanoma, Gastrointestinal perforation, Anemia (2-4%), Arterial thrombosis, Decreased lymphocyte count (0.04%), Deep venous thrombosis, Neutropenia (0.07%), Hepatotoxicity, Infectious disease (20-22%), Malignant lymphoma, Opportunistic infection, Post-transplant lymphoproliferative disorder, Epstein Barr virus associated (2.3%), Tuberculosis, Cerebrovascular accident, Lung cancer, Pulmonary embolism, Cancer |
| Pregnancy          | No (Limited) Human Data – Animal Data Suggest Low Risk                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |
| Lactation          | No (Limited) Human Data - Potential Toxicity                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                          |
| More Info          | [UpToDate](https://www.uptodate.com/contents/tofacitinib-drug-information)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                            |

